Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial SWOG 1001

Title
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
Principal Investigator
Adam M Petrich
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.SWOG 1001
Purpose
Limited (or early) Stage Diffuse Large B-cell Lymphoma (DLBCL) is curable in many people, but some still relapse, and some develop side-effects after treatment. This study uses a radiologic test called PET/CT scan after initial standard chemotherapy (R-CHOP) to help individualize subsequent treatment in the hope of improving cure rates while decreasing side effects of treatment.
Overview
Standard chemotherapy "R-CHOP" for DLBCL will be followed up with a full body PET/CT scan to determine if there is active disease. If the PET/CT scan shows active lymphoma then those participants will receive more intensive treatment than those who have inactive disease after chemotherapy.
Eligibility
Some of the eligibility criteria include:
  • Participant's diagnosis of Diffuse Large B-cell Lymphoma must have been proven by biopsy.
  • Participants must be 18 years old or older.
  • Participants must not have received prior chemotherapy, radiation or antibody therapy for lymphoma.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will receive 3 cycles (21 days each) of standard chemotherapy called "R-CHOP" (FDA approved drugs doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab). After completing the 3 cycles of chemotherapy, participants will have a full body PET/CT scan. If the review of the PET/CT scan shows that disease is likely inactive, participants will receive an additional cycle (21 days) of R-CHOP for consolidation. If the review of the PET/CT scan shows that disease may still be active, then participants will receive radiation therapy to areas of the body with evidence of lymphoma, followed by a drug regimen called Yttrium-90 ibritumomab tiuxetan (Zevalin®). Follow-up visits will be every 6 months for 2 years and then yearly for a maximum of 7 years from the time participants entered the study.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Adam M Petrich

last updated: 23-Sep-14 03:23 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.